Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 16 February 2026 - 15:49

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/201

Submitted by Anonymous (not verified) on 16 February 2026 - 15:00

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 16 February 2026 - 14:40

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised

Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026

Submitted by Anonymous (not verified) on 16 February 2026 - 14:38

Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026

Human medicines European public assessment report (EPAR): Dovato, dolutegravir,lamivudine, Date of authorisation: 01/07/2019, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 16 February 2026 - 13:42

Human medicines European public assessment report (EPAR): Dovato, dolutegravir,lamivudine, Date of authorisation: 01/07/2019, Revision: 20, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More